<p>新澤西州伊瑟林，2025 年 12 月 26 日（環球新聞通訊社）——Outlook Therapeutics, Inc.（納斯達克：OTLK），一家專注於提升貝伐單抗在視網膜疾病治療中標準護理的生物製藥公司，今天宣佈，自 2025 年 12 月 19 日起，Outlook Therapeutics, Inc.董事會薪酬委員會向兩名新員工授予了購買共計 150,000 股 Outlook Therapeutics 普通股的股票期權，行使價格為每股 2.01 美元。</p>
<p>上述獎勵是根據納斯達克上市規則 5635(c)(4) 作為員工入職公司的誘因而授予的。</p>
<p><strong>關於 Outlook Therapeutics, Inc.</strong></p>
<p>Outlook Therapeutics 是一家生物製藥公司，專注於 ONS-5010/LYTENAVA™（貝伐單抗-vikg，貝伐單抗 gamma）的開發和商業化，以提升貝伐單抗在視網膜疾病治療中的標準護理。LYTENAVA™（貝伐單抗 gamma）是首個獲得歐洲委員會和 MHRA 批准用於治療濕性年齡相關性黃斑變性（濕性 AMD）的貝伐單抗眼用製劑。Outlook Therapeutics 已在德國和英國開始 LYTENAVA™（貝伐單抗 gamma）用於濕性 AMD 的商業發佈。</p>
<p>在美國，ONS-5010/LYTENAVA™（貝伐單抗-vikg）仍處於研究階段。如果在美國獲得批准，ONS-5010/LYTENAVA™將成為首個獲批用於視網膜適應症（包括濕性 AMD）的貝伐單抗眼用製劑。</p>
<p><strong>投資者諮詢：</strong> Jenene Thomas</p>
<p>首席執行官</p>
<p>JTC Team, LLC</p>
<p>電話：908.824.0775</p>
<p>OTLK@jtcir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZ3pPQ00zTXpNMU5EQTFJekl3TWpnNE1qST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZ3pPQ00zTXpNMU5EQTFJekl3TWpnNE1qST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmI4ODU1ZmItNTAyNC00Yjg4LWEwMDctYTMxY2JkMWIxMGI3LTEwNDAzOTMtMjAyNS0xMi0yNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmI4ODU1ZmItNTAyNC00Yjg4LWEwMDctYTMxY2JkMWIxMGI3LTEwNDAzOTMtMjAyNS0xMi0yNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png"/></p>

OTLK

<p>Outlook Therapeutics 宣佈新的就業誘因獎勵，將於 2025 年 12 月 19 日生效。公司的薪酬委員會向兩名新員工授予了以每股 2.01 美元購買 150,000 股股票的期權。這些獎勵是根據 NASDAQ 上市規則 5635(c)(4) 作為就業誘因給予的</p>

<p>ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees.</p>
<div class="lb-trans"><p>新澤西州伊瑟林，2025 年 12 月 26 日（環球新聞通訊社）——Outlook Therapeutics, Inc.（納斯達克：OTLK），一家專注於提升貝伐單抗在視網膜疾病治療中標準護理的生物製藥公司，今天宣佈，自 2025 年 12 月 19 日起，Outlook Therapeutics, Inc.董事會薪酬委員會向兩名新員工授予了購買共計 150,000 股 Outlook Therapeutics 普通股的股票期權，行使價格為每股 2.01 美元。</p>
</div><p>The above-described awards were granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>上述獎勵是根據納斯達克上市規則 5635(c)(4) 作為員工入職公司的誘因而授予的。</p>
</div><p><strong>About Outlook Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Outlook Therapeutics, Inc.</strong></p>
</div><p>Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retinal diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD (wet age-related macular degeneration). Outlook Therapeutics commenced the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the treatment of wet AMD.</p>
<div class="lb-trans"><p>Outlook Therapeutics 是一家生物製藥公司，專注於 ONS-5010/LYTENAVA™（貝伐單抗-vikg，貝伐單抗 gamma）的開發和商業化，以提升貝伐單抗在視網膜疾病治療中的標準護理。LYTENAVA™（貝伐單抗 gamma）是首個獲得歐洲委員會和 MHRA 批准用於治療濕性年齡相關性黃斑變性（濕性 AMD）的貝伐單抗眼用製劑。Outlook Therapeutics 已在德國和英國開始 LYTENAVA™（貝伐單抗 gamma）用於濕性 AMD 的商業發佈。</p>
</div><p>In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.</p>
<div class="lb-trans"><p>在美國，ONS-5010/LYTENAVA™（貝伐單抗-vikg）仍處於研究階段。如果在美國獲得批准，ONS-5010/LYTENAVA™將成為首個獲批用於視網膜適應症（包括濕性 AMD）的貝伐單抗眼用製劑。</p>
</div><p><strong>Investor Inquiries:</strong> Jenene Thomas</p>
<div class="lb-trans"><p><strong>投資者諮詢：</strong> Jenene Thomas</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席執行官</p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>T: 908.824.0775</p>
<div class="lb-trans"><p>電話：908.824.0775</p>
</div><p>OTLK@jtcir.com</p>
<div class="lb-trans"><p>OTLK@jtcir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZ3pPQ00zTXpNMU5EQTFJekl3TWpnNE1qST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjgzOCM3MzM1NDA1IzIwMjg4MjI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmI4ODU1ZmItNTAyNC00Yjg4LWEwMDctYTMxY2JkMWIxMGI3LTEwNDAzOTMtMjAyNS0xMi0yNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NmI4ODU1ZmItNTAyNC00Yjg4LWEwMDctYTMxY2JkMWIxMGI3LTEwNDAzOTMtMjAyNS0xMi0yNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png"/></p>

Outlook Therapeutics 宣佈新的就業激勵授予 | OTLK 股票新聞